Shwachman-Diamond syndrome (SDS) is a rare genetic disorder characterized by pancreatic insufficiency, short stature, skeletal abnormalities and bone marrow dysfunction. Shwachman et al 1 described the syndrome in 1964 in a family with two affected brothers and an affected sister with pancreatic insufficiency. Although SDS resembles cystic fibrosis with respect to pancreatic exocrine insufficiency, in SDS sweat electrolytes are normal and chronic lung disease is not typical. 1 Also, in contrast to cystic fibrosis, patients with SDS have a spectrum of hematological abnormalities, most commonly neutropenia. Additionally, patients may develop other cytopenias, severe aplastic anemia, myelodysplasia and leukemic transformation. [2] [3] [4] Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for the hematologic disturbances of SDS; however, our review of the literature reveals limited survival with transplant, with only seven of 15 reported cases alive post HSCT. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Poor outcome with HSCT is frequently related to excessive cardiac and other organ toxicity from the preparative therapy. We describe two young children with SDS who underwent successful allografting using a non-cardiotoxic conditioning regimen. In the first case, hematopoietic reconstitution was accomplished using marrow from an HLA-identical sibling. The second case, to the best of our knowledge, represents the first reported case of successful HSCT using an unrelated cord blood donor in a SDS patient.
Case reports

Patient 1
A 4-year-old female was diagnosed with SDS at 10 months of age. She was born prematurely at 34 weeks and was small for gestational age. She remained chronically ill from birth. In the perinatal period she developed hypoglycemia and respiratory distress. She continued to have difficulties with diarrhea, failure to thrive, vomiting, poor oral intake and frequent respiratory infections. A gastrostomy tube was placed for enteral nutritional support. Hepatic steatosis and mild periportal fibrosis were found on liver biopsy. At 10 months of age a diagnosis of SDS was made, when her evaluation revealed fatty replacement of the pancreas on CT imaging, markedly reduced serum trypsinogen, steatorrhea, characteristic bone changes, abnormal dentition and previous thrombocytopenia. A sweat chloride test for cystic fibrosis was negative. CBC revealed only mild normocytic anemia. Pancreatic enzyme and fat-soluble vitamin supplementation was initiated.
At 18 months of age she developed pancytopenia. Bone marrow examination showed normal overall cellularity with mild granulocytic hypoplasia with maturation arrest and mild megakaryocytic hypoplasia. Over the next few months she remained neutropenic and had increasing difficulties with thrombocytopenia and anemia. At 22 months of age CBC showed macrocytosis, hemoglobin 7.6 g/dl, WBC 3500/mm 3 and platelet count 9000/mm 3 . Absolute neutrophil count (ANC) was 315/mm 3 and reticulocyte count was 0.7%. Repeat bone marrow examination revealed progressive hypoplasia without evidence of leukemic transformation. Cytogenetic studies including fluorescent in situ hybridization (FISH) showed a normal karyotype with no abnormalities of chromosome 5 or 7.
At 22 months of age, the patient was referred for allogeneic bone marrow transplantation (BMT) for treatment of her aplastic anemia. Her 4-year-old brother, who was HLA-genotypically identical to the patient, was selected to serve as the bone marrow donor. Thorough evaluation of the donor, including physical examination, blood count, CT scan of the pancreas and serum trypsinogen level, revealed no stigmata of SDS.
Transplant preparative therapy for severe aplastic anemia with cyclophosphamide and anti-thymocyte globulin (ATG) was planned. However, during the initial 12 h of pre-chemotherapy hydration (3000 cc 3 /m 2 /24 h), the patient developed congestive heart failure. Therefore, it was felt to be ill advised to proceed with cyclophosphamide-based therapy due to its cardiotoxic potential. The patient received furosemide for diuresis, her condition improved and she was discharged for re-evaluation and development of a new preparative therapy plan.
Cardiac evaluation prior to development of congestive heart failure had shown mild abnormalities without a clear contraindication to transplant. EKG showed possible right ventricular hypertrophy and nonspecific S-T wave changes. Echocardiogram showed mild left atrial and left ventricular enlargement with normal resting fractional shortening of 32%. However, during a dobutamine stress study, the fractional shortening failed to increase with drug-induced tachycardia, consistent with subclinical cardiomyopathy.
Ianotropic support with digoxin and afterload reduction with captopril were initiated. In addition, the preparative regimen was revised to employ agents with less cardiotoxic potential. The new conditioning program consisted of melphalan (60 mg/m 2 /day) and etoposide (400 mg/m 2 /day) on days −6, −5 and −4 plus ATG (30 mg/kg/day) and methylprednisolone (2 mg/kg/day) on days −3, −2 and −1 followed by methylprednisolone taper with discontinuation on day +2. The patient tolerated the preparative therapy without serious cardiac toxicity. The patient's regimen-related toxicities included grade II gastrointestinal toxicity manifesting as diarrhea and grade II stomatitis. Graft-versus-host disease (GVHD) prophylaxis with cyclosporine alone was initiated on day −1. On day 0 (07/01/1998), the patient received 5 × 10 8 total nucleated bone marrow cells per kilogram from her HLA-identical brother.
On day +10, she developed an extensive red macular/papular rash consistent with grade 2 acute GVHD involving the skin only. Skin biopsy confirmed the diagnosis. The rash promptly resolved with the addition of intravenous methylprednisolone therapy.
Myeloid engraftment (ANC Ͼ500/mm 3 ) occurred on day +10 and platelet independence (count Ͼ50 000/mm 3 without transfusion for 7 days) was achieved on day +26. Cyclosporine and steroid therapies were tapered and discontinued by day + 279. The patient developed no findings of chronic GVHD. Resting cardiac function has remained normal on repeat echocardiogram with a shortening fraction of 35% at day +12 and 33% at 8 months post transplant. The patient continued to have significant problems with gastroesophageal reflux and poor weight gain and subsequently underwent laproscopic fundoplication and gastrostomy placement. She is currently doing well, now 36 months post HSCT, with excellent hematopoietic function and improving nutritional status on gastrostomy feedings. Chimerism studies using FISH to determine XX:XY ratio was done on marrow at day +21 post HSCT and showed 100% of nucleated cells to be of donor origin. FISH was done on peripheral blood at 12 months post-HSCT and again showed full donor chimerism.
Patient 2
A 2-year-old female presented at 3 months of age with fever, diarrhea, failure to thrive and neutropenia. Diagnostic testing revealed undetectable serum pancreatic enzymes (amylase, lipase, serum trypsin-like immunoreactivity) and abnormal bone marrow findings with myeloid arrest at the promyelocytic stage and decreased megakaryocytes. Chromosomal breakage studies were normal and no cytogenetic abnormalities were detected. A skeletal survey revealed no bony abnormalities. An abdominal CT scan demonstrated fatty replacement of the pancreas. Despite therapy with high-dose G-CSF (up to 50 g/kg/day), the patient remained severely neutropenic with recurrent lifethreatening infections, including necrotizing enterocolitis, intestinal candidiasis, multiple soft tissue abscesses, and bacteremia. Because of the severity of these infections and persistent marrow aplasia, she was referred for HSCT at 12 months of age. A CBC at that time revealed a hemoglobin of 9.8 g/dl, an MCV of 89, platelet count of 109 000/mm 3 , WBC count of 10 600/mm 3 and an ANC of 212/mm 3 . The patient lacked an HLA-identical family member, and a search through bone marrow registries failed to reveal any perfectly matched unrelated donors. Therefore, umbilical cord blood from a partially matched, unrelated donor was chosen as the hematopoietic stem cell source. Donor and recipient were matched for five of six HLA-A, B and DR antigens and mismatched for a single HLA-A antigen. The pair was matched for HLA-DR and DQ alleles by high resolution molecular typing. No cardiac abnormalities were noted on the pretransplant workup.
The same preparative regimen was used as in case 1, with the addition of total lymphoid irradiation (TLI), 500 cGy on day −1. On day 0 (09/09/99), the patient received 7.65 × 10 7 total nucleated cord blood cells per kilogram. GVHD prophylaxis consisted of cyclosporine and methylprednisolone. The patient developed grade III mucositis secondary to the preparative therapy consisting of oropharyngeal changes, diarrhea reaching 16 cc she still needed parenteral nutrition to help her meet caloric goals. She developed tachycardia and tachpnea on day +5 with no hypoxia, a normal EKG, a normal echocardiogram, and a clear chest X-ray with no cardiomegaly. Retrospectively, these changes in her vital signs were felt to be due to stress from mucositis. The tachycardia and tachypnea resolved without specific intervention over the ensuing week. She developed a transient rise in her ALT and total bilirubin to 92 and 1.2, respectively, on the day of transplant, felt to be a side-effect of chemotherapy. She did not develop clinical evidence of hepatic veno-occlusive disease, and the liver function tests subsequently normalized. Other complications included Enterobacter cloacae sepsis on day +8, and grade 2 acute GVHD (confirmed by duodenal biopsy) on day +28. Myeloid engraftment (ANC Ͼ500/mm 3 ) occurred on day +18 and platelet independence (Ͼ50 000/mm 3 without transfusion for 7 days) was achieved on day +46. The patient is presently doing well, now 22 months post HSCT. She has normal blood counts without any evidence of chronic GVHD. FISH analysis of marrow at 6 months post HSCT revealed complete donor chimerism.
Discussion
In 1964 Shwachman et al 1 described a syndrome of pancreatic insufficiency, bone marrow dysfunction and skeletal abnormalities. With the reporting of additional cases and further description of the clinical findings, the disorder has come to be known as Shwachman-Diamond syndrome. 17, 18 Various hematologic abnormalities may occur in SDS. These include cytopenias of varying severity, frank bone marrow aplasia, bone marrow cytogenetic abnormalities, myelodysplasia, and leukemic transformation, most commonly to acute myelogenous leukemia (AML). 3, 4, 8 A recent review by Ginzberg et al 19 identified 88 patients with SDS diagnosed between 1992 and 1997. Patients were included only if objective evidence of both exocrine pancreatic insufficiency and hematologic dysfunction were found. The diagnosis of pancreatic insufficiency was accepted if the patient had depressed serum cationic trypsinogen, and abnormal 72-h fecal fat balance study plus characteristic pancreatic abnormalities on imaging studies, or decreased pancreatic enzyme secretion by quantitative pancreatic stimulation test. Hematologic dysfunction was defined as having depression of one or more hematopoietic cell lines, including hemoglobin Ͻ10 g/dl, neutrophil count Ͻ1500/mm 3 and/or platelet count Ͻ150 000/mm 3 . Patients were excluded if they fulfilled criteria compatible with an alternate diagnosis such as cystic fibrosis.
Among patients followed in the above report, neutropenia occurred in 86 of 88 patients (98%), while pancytopenia occurred in 20% of patients. Forty patients had available bone marrow results, of which only six were reported as normal. Twenty-four specimens were hypocellular, 12 showed maturation delay or arrest of the myeloid series, and four demonstrated myelodysplasia. Clonal cytogenetic abnormalities were found in six patients (three with monosomy 7, one with isochromosome 7, one with isochromosome 7 plus deletion of 20q, and one with deletion of 1(p34-p36)).
HSCT can be curative for the hematologic manifestations of SDS. However, there are few reports in the literature of successful transplantation in patients with SDS (Table 1) . To this point, all reported cases have used bone marrow as the stem cell source. The first reported case of HSCT for bone marrow failure in a patient with SDS was published by Tsai et al 5 in 1990 . In their report, a 10-year-old boy with Shwachman syndrome and severe bone marrow failure was treated with high-dose cyclophosphamide, busulfan, and antithymocyte globulin (ATG) followed by infusion of matched sibling bone marrow. He developed cardiac arrhythmias and intractable hypotension and died on day 23 post transplant.
A review of the published literature discovered 15 cases of SDS that received an allogeneic HSCT. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Donors were HLA-matched siblings in five cases, unrelated individuals in eight cases, and a mismatched relative in one case. The stem cell source was bone marrow in each of these cases. The donor type was not reported in one case. Of these 15 cases, seven (46.7%) are reported as alive. The longest follow-up period reported in surviving patients was 20 months post HSCT with the range of follow-up being 3 to 20 months. 6, 8, 9, 12, [14] [15] [16] Long-term survival data were not available for the majority of cases reported. When listed, the causes of death were congestive heart failure (1), infection (3), multi-organ failure (1), respiratory failure (1) and pulmonary hemorrhage (2).
Barrios et al 6 in 1991 reported the first successful transplant in a patient with SDS. Their patient underwent BMT at 17 years of age for progressive pancytopenia. She received matched sibling bone marrow after a preparative regimen of total lymphoid irradiation and cyclophosphamide. Her follow-up at time of report was 9 months.
The severe regimen-related toxicity which these patients may experience was emphasized in a case reported by Bunin et al. 9 This child was diagnosed with SDS at 2 months of age. T cell-depleted, unrelated marrow transplantation (mismatched at the HLA-A locus) following conditioning with total body irradiation (TBI), Ara-C and cyclophosphamide was performed for aplastic anemia. The patient developed severe hepatic veno-occlusive disease and hepato-renal syndrome. The child underwent related liver transplantation on day +33 with the left lateral segment of her mother's liver. At 9 months post-liver transplant, and 10 months post-BMT the patient had good hematopoietic engraftment, was transfusion independent, and had normal liver function.
Of the additional 12 patients with SDS in our review, six patients underwent bone marrow transplantation for myelodysplasia, 8, 13, 14 and five patients as treatment for leukemia, four patients with AML 8,10-12 and one patient with ALL. 16 In one patient, the indication for BMT was not given. 15 Collectively, among these previously reported cases of HSCT for SDS, eight of 15 (53%) patients died between 23 days and 1 year following transplantation. Two patients developed fatal infections. One patient experienced graft failure and died. One patient died of cardiac toxicity. One patient developed a relapse of their AML 9 months post HSCT and died of multi-organ failure. One patient died of respiratory failure 2 months after bone marrow transplan- tation. Two patients receiving the same conditioning regimen of thiotepa, cytoxan and total body irradiation, died of pulmonary hemorrhage. Donor type did not clearly impact upon survival. Eight patients received marrow from matched unrelated donors (MUD), of whom four (50%) are alive. Matched sibling donor marrow transplants were performed in five patients with two survivors reported. One patient received a related, mis-matched marrow transplant and died of complications. One patient is alive 20 months after allogeneic bone marrow transplantation in which the donor type was not specified.
While type of transplant received did not impact survival, the indication for transplant may affect outcome. Patients who underwent HSCT for bone marrow aplasia had the best outcome with two of three patients (67% survival) reported alive post HSCT. In contrast, four of six patients (33% survival) who underwent HSCT for myelodysplastic syndrome died, and three of five (40% survival) with leukemia died of their disease or from toxicity.
In our review, cardiac toxicity was a cause of death post HSCT. One of our patients (case 1) experienced cardiac dysfunction with fluid challenge prior to receiving chemotherapy. Literature on SDS suggests that patients with SDS have an increased risk of cardiac disease even prior to undergoing HSCT. In a review of 16 untransplanted patients diagnosed with SDS in Finland, eight died of cardiac failure. 20 An additional patient had transient cardiac failure. In five cases, the development of cardiac failure was rapid and death occurred within 2 days. At autopsy, the myocardium contained numerous small necrotic foci with microabscesses in one case. The remaining cases all had lesions within the left ventricular wall and interventricular septum. On sectioning, these lesions showed destruction of the myofibers. 20 The basis for cardiac disease in SDS is unclear, but could be genetically determined or due to nutritional factors, such as carnitine deficiency. These reports suggest that cardiac function should be thoroughly evaluated and considered when choosing a conditioning regimen for HSCT in SDS.
We conclude that allogeneic HSCT can offer cure for hematopoietic failure and hematologic malignancy in patients with Shwachman-Diamond syndrome. Various stem cell sources including marrow and cord blood from related and unrelated donors are feasible options for HSCT in these patients. Less cardiotoxic conditioning regimens, such as the melphalan, etoposide and ATG program described here, should be considered for use in patients with SDS. With early transplantation, prior to the development of myelodysplasia or leukemic transformation, and careful attention to preventing regimen-related toxicity from preparative therapy, it may be possible to treat the hematologic disorders of SDS more successfully by HSCT.
